Comparative Pharmacological Study of Statins in Hyperlipidemia

Abstract

Hyperlipidemia is regarded as one of the leading risk factors of cardiovascular diseases and statins are trendy to regulate the elevated levels of lipids by inhibiting the action of HMG-Coa reductase. Lipid-lowering agents include atorvastatin, simvastatin and rosuvastatin and have already been established to play a relatively similar role with reference to hyperlipidemic Wistar rats as has been established in this study. The high-fat ration has been exposed to 50 male rats which are randomly divided into four slices and hyperlipidemia is developed. The value of the statins has been determined after 28 days and at initiation and end of treatment of the lipid parameters which include the total cholesterol(TC), triglycerides(TG), total low density lipoprotein cholesterol (LDL-C) and total high density lipoprotein cholesterol (HDL-C). The findings showed that the statins and TC TG LDL- C and HDL- C rise were gigantic in all statin treated groups except hyperlipidemic controls in the topmost level with the most effective statin being rosuvastatin. Post hoc and one-way ANOVA confirmed significantly different statins when rejecting the null hypothesis and confirmed further difference between the statins. The results add preclinical supporting information to the higher lipid-lowering capacity of rosuvastatin and could offer comparative information on future pharmacological studies and the improvement of the catheterization approaches in fighting lipid hypercarbohydrates in animals.